16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in...
16:30 , Sep 21, 2018 |  BC Week In Review  |  Financial News

argenx prices $300M follow-on

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $300.6 million in a follow-on that priced after hours on Sept. 18. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its NASDAQ close of $93.77 on Sept. 17,...
17:34 , Sep 19, 2018 |  BC Extra  |  Financial News

argenx, G1 price follow-ons, CRISPR proposes

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) and G1 Therapeutics Inc. (NASDAQ:GTHX) raised $300.6 million and $180 million, respectively, in follow-ons that priced after hours Tuesday. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its NASDAQ...
22:45 , Sep 17, 2018 |  BC Extra  |  Clinical News

argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
17:39 , Apr 20, 2018 |  BioCentury  |  Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
16:38 , Dec 15, 2017 |  BC Week In Review  |  Financial News

argenx raises $231M in follow-on

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $231 million through the sale of 4.4 million ADSs at $52 in a bumped-up follow-on underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. The price is...
03:50 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

argenx reports Phase II myasthenia gravis data for ARX-113

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported top-line data from a Phase II study in 24 myasthenia gravis patients showing that 75% of patients treated with efgartigimod (ARGX-113) achieved at least a 2 point reduction from baseline...